Appointment of Corporate Broker

28th February, 2013

BEXIMCO PHARMACEUTICALS LTD.

Appointment of Corporate Broker

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces the appointment of Daniel Stewart & Company plc as corporate broker alongside its existing nominated adviser, Libertas Capital Corporate Finance Limited. The appointment takes place with immediate effect.

Ends

For further enquiries please contact:

Beximco Pharma

Nazmul Hassan MP, Managing DirectorTel: +880 2 861 9151, ext.2080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel: +880 2 8618220-1, Ext 1140

Libertas Capital Corporate Finance

Thilo Hoffmann

Tel: +44 (0)20 7569 9650

Daniel Stewart & Company (Broker)

Paul Shackleton

James Thomas

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway / Susan Stuart / Victoria Foster-MitchellTel: +44 (0)20 7269 7169

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.